#Paris #France #Astraveus #Lakhesys #Didier Masson

Astraveus Strengthens Leadership Team for Innovative Development

Astraveus SAS, a pioneering company specializing in the innovative Lakhesys Benchtop Cell Factory™, is taking significant strides in its development by enhancing its leadership team. This strategic move comes as the company strives to revolutionize the cell therapy manufacturing landscape through advanced technology and operational excellence.

On October 21, 2025, Astraveus announced the appointment of two distinguished industry leaders: Didier Masson as Chief Operating Officer and Ken Kotz as Chief Technology Officer.

Key Appointments Driving Growth

Didier Masson - Chief Operating Officer

Didier Masson brings over 20 years of operational excellence across diverse sectors including pharmaceuticals, biotechnology, and medical technology. He previously held the title of COO at Quantoom Biosciences, where he was instrumental in scaling operations. At Astraveus, he will focus on enhancing the Lakhesys Benchtop Cell Factory™ capabilities, advancing program management, manufacturing, and supply chain management. His extensive experience in bioprocessing will be vital as Astraveus pursues sustainable growth and operational excellence.

Didier expressed optimism about his new role, stating, “I see a tremendous opportunity to contribute to the growth of Astraveus by optimizing operations, building scalable systems, and promoting collaboration across teams. The company's mission truly resonates with me, and I look forward to driving operational excellence.”

Ken Kotz - Chief Technology Officer

Ken Kotz also joins Astraveus with an impressive background in driving innovation within the life sciences sector. With over 20 years of experience, he specializes in microfluidic bioprocessing and product development, having held senior roles at bluebird bio among others. His expertise is particularly significant as he contributed to the commercialization of Lyfgenia™, a groundbreaking cell therapy product.

Ken’s passion for advancing cell therapy manufacturing aligns perfectly with Astraveus's goals. He remarked, “Astraveus' automated approach to cell therapy manufacturing has the potential to transform the landscape of autologous cell and gene therapies. I am dedicated to expanding access to these transformative medicines for patients in need.”

Momentum and Future Aspirations

Jérémie Laurent, CEO of Astraveus, emphasized the company's ambition to attract top talent, which serves as a testament to their vision of providing high-quality, accessible cell therapies. “Didier and Ken will play pivotal roles as we advance the development of our Lakhesys Benchtop Cell Factory,” he stated.

The integration of these seasoned leaders complements the previous appointments made earlier this year, which included Jean-Paul Mangeolle as Chairman of the Board, David Newble as an Independent Board Member, and Laurence Riot Lamotte as Chief Financial Officer.

About Astraveus

Founded in 2016 by Jérémie Laurent at the Saint-Louis Hospital in Paris, Astraveus is dedicated to revolutionizing cell therapy manufacturing. The company’s unique Lakhesys Benchtop Cell Factory™ leverages cutting-edge microfluidic technology to streamline and enhance bioprocessing, aiming to make innovative treatments accessible to everyone in need. By maximizing quality and speed while reducing costs, Astraveus aspires to revolutionize the future of healthcare.

As Astraveus embarks on this transformative journey, the leadership team is poised to lead the company towards an era of enhanced patient care through innovative therapies. The commitment to operational excellence, along with strong talent, positions Astraveus as a key player in the ongoing evolution of the life sciences industry.